In Vitro Activity of Lefamulin against Sexually Transmitted Bacterial Pathogens

  • Antimicrob Agents Chemother. 2018 Apr 26;62(5):e02380-17. doi: 10.1128/AAC.02380-17.
Susanne Paukner  1 ,  Astrid Gruss  2 ,  Jørgen Skov Jensen  3
Affiliations
  • 1. Nabriva Therapeutics GmbH, Vienna, Austria [email protected].
  • 2. Nabriva Therapeutics GmbH, Vienna, Austria.
  • 3. Statens Serum Institut, Microbiology and Infection Control, Copenhagen, Denmark.
PMID: 29530863 DOI: 10.1128/AAC.02380-17
Abstract

The pleuromutilin Antibiotic lefamulin demonstrated in vitro activity against the most relevant Bacterial pathogens causing sexually transmitted infections (STI), including Chlamydia trachomatis (MIC50/90, 0.02/0.04 mg/liter; n = 15), susceptible and multidrug-resistant Mycoplasma genitalium (MIC range, 0.002 to 0.063 mg/liter; n = 6), and susceptible and resistant Neisseria gonorrhoeae (MIC50/90, 0.12/0.5 mg/liter; n = 25). The results suggest that lefamulin could be a promising first-line Antibiotic for the treatment of STI, particularly in populations with high rates of resistance to standard-of-care Antibiotics.

Keywords
Chlamydia trachomatis; Mycoplasma genitalium; Neisseria gonorrhoeae; lefamulin; pleuromutilin; sexually transmitted diseases; sexually transmitted infection.
Products